UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement.
Analysts estimate that UroGen Pharma will report an earnings per share (EPS) of $-1.17.
UroGen Pharma bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Past Earnings Performance
Last quarter the company missed EPS by $0.06, which was followed by a 7.46% drop in the share price the next day.
Here's a look at UroGen Pharma's past performance and the resulting price change:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | -1.29 | -1.27 | -1.29 | -1.37 |
| EPS Actual | -1.35 | -1.17 | -1.17 | -1.38 |
| Price Change % | -7.46% | 1.57% | -1.17% | 10.64% |
Stock Performance
Shares of UroGen Pharma were trading at $9.09 as of March 17. Over the last 52-week period, shares are down 53.1%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
To track all upcoming earnings announcements, click here to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
